Health News

GENEVA--(BUSINESS WIRE)--Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the fir...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE: CVS). (Please see below for a detailed listing of the compani...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed at the Company's website at www.sinovac.com.cn or www.sinovac.com and at the SEC’s website www.sec.gov. The Company also...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practi...

SHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data demonstrated robust weight reduction, preservation of lean mass, reduced weight regain following treatment discontinuation and the potential for extended dosing intervals. CC-18 is designed to address a growing challenge in...

BOULDER, Colo.--(BUSINESS WIRE)--At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories has been studying skin cells to better understand what supports the visible qualities associated with healthier-looking, more resilient skin over time. While much of the longevity conversation has centered on high-profile molecules associated with NAD+ and “breakthrough” molecules, AV Laboratories’ recent research points back to something more fundamental: amino acids. Wi...

BOSTON--(BUSINESS WIRE)--Brighton Marine today announced the appointment of Brian J. Ewart as General Counsel. Ewart will provide strategic legal counsel and oversight across Brighton Marine and its affiliated enterprises, supporting the organization’s healthcare, housing, and wraparound service initiatives for veterans and military-connected families. Ewart joined Brighton Marine as Deputy General Counsel and has played a key role guiding and supporting the organization’s legal, compliance, go...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres...

MANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society (SIRS). This recognition celebrates his decades-long contributions that have transformed the understanding, treatment and outcomes for individuals living with schizophrenia worldwide. The SIRS Lifetime Achievement Award is one of...

AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application (MAA) for AQNEURSA® (levacetylleucine) to include the treatment of Ataxia-Telangiectasia (A-T). This submission represents the first regulatory application submitted to the EMA seeking approval of a therapy for the treatment of A-T, a rare, progressive, inherited neurodegenerative disorder. The v...